EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, UCBJY: Ucb ADR

15 Oct 2025
LAST:

149.5

CHANGE:
 0.62		OPEN:
149.0		HIGH:
150.2		ASK:
0.0		VOLUME:
18.4K
CHG(%):
0.41		PREV:
150.1		LOW:
148.9		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 25149.0150.2148.9149.518.4K
14 Oct 25148.7150.9148.4150.118.2K
13 Oct 25149.5150.6149.5150.214.7K
10 Oct 25148.3149.1147.9148.938.1K
09 Oct 25151.4151.8149.9150.123.9K
08 Oct 25149.7149.8148.6149.259.3K
07 Oct 25147.1148.2146.5147.354.2K
06 Oct 25149.5149.9148.1148.325.5K
03 Oct 25148.0148.5147.6147.616.4K
02 Oct 25144.9144.9143.1144.319.4K

COMPANY PROFILE

Name:Ucb ADR
About:UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Sector:Healthcare
Industry:Biotechnology
Address:Allée de la Recherche, 60, Brussels, Belgium, 1070
Website:https://www.ucb.com
CIK:0001290640
ISIN:US9034801012
FIGI:BBG000CL15T5
LEI:2138008J191VLSGY5A09

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:36.62 
Forward P/E:25.77 
DivYield:0.01 
Div/Share:1.39 
Price to Book:4.82 
Price to Sales:8.20 
EBITDA:1.852B 
Shares:379.99M 
Market Cap:56.796B 

TECHNICAL INDICATORS

MA5:149.760.2%
MA10:148.540.6%
MA20:136.949.1%
MA50:124.4320.1%
MA100:111.0834.6%
MA200:101.8946.7%
STO9:49.05
STO14:93.70 
RSI14:90.78 
WPR14:-2.24 
MTM14:34.07
ROC14:0.30 
ATR:4.06 
Week High:151.761.5%
Week Low:147.851.1%
Month High:151.761.5%
Month Low:114.5346.7%
Year High:151.761.5%
Year Low:71.16110.1%
Volatility:2.27